VYNE Therapeutics Inc. (VYNE)
NASDAQ: VYNE · IEX Real-Time Price · USD
2.720
-0.170 (-5.88%)
May 8, 2024, 1:55 PM EDT - Market open
Company Description
VYNE Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on developing proprietary and therapeutics for the treatment of immuno-inflammatory conditions.
The company's lead product is VYN201, a locally administered pan- bromodomain and extra-terminal (BET) inhibitor soft drug to address diseases involving multiple, diverse inflammatory cell signaling pathways with low systemic exposure.
It also develops VYN202, a BD2-selective oral small molecule BET inhibitor for the treatment of immuno-inflammatory indications.
The company was formerly known as Menlo Therapeutics Inc. and changed its name to VYNE Therapeutics Inc. in September 2020.
VYNE Therapeutics Inc. was founded in 2003 and is based in Bridgewater, New Jersey.
VYNE Therapeutics Inc.
| Country | United States |
| Founded | 2003 |
| IPO Date | Jan 25, 2018 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 10 |
| CEO | David T. Domzalski |
Contact Details
Address: 685 Route 202/206 N., Suite 301 Bridgewater, New Jersey 08807 United States | |
| Phone | 800-775-7936 |
| Website | vynetherapeutics.com |
Stock Details
| Ticker Symbol | VYNE |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001566044 |
| CUSIP Number | 92941V209 |
| ISIN Number | US92941V3087 |
| Employer ID | 45-3757789 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| David T. Domzalski | Chief Executive Officer, President and Director |
| Dr. Iain A. Stuart Ph.D. | Chief Scientific Officer |
| Mutya Harsch J.D. | General Counsel, Chief Legal Officer and Company Secretary |
| Tyler Zeronda | Chief Financial Officer and Treasurer |
| Dr. Darrell S. Rigel Faad, M.D., Ms | Consultant |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Mar 14, 2024 | EFFECT | Notice of Effectiveness |
| Mar 6, 2024 | UPLOAD | Filing |
| Mar 1, 2024 | S-3 | Registration statement under Securities Act of 1933 |
| Mar 1, 2024 | S-8 | Securities to be offered to employees in employee benefit plans |
| Mar 1, 2024 | 10-K | Annual Report |
| Feb 29, 2024 | 8-K | Current Report |
| Feb 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Feb 2, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Jan 3, 2024 | 8-K | Current Report |
| Dec 13, 2023 | S-8 | Securities to be offered to employees in employee benefit plans |